Glabellar Botulinum Toxin Injection

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Indications

Primary Indications

Reduction of glabellar frown lines (cosmetic)Adjunctive treatment for major depression (investigational)

Mechanism

Botulinum toxin blocks acetylcholine release at neuromuscular junctions, leading to localized muscle relaxation. In psychiatry, its hypothesized antidepressant effect is based on the facial feedback hypothesis, which posits that reducing negative facial expressions decreases negative emotional signaling to the brain.

Protocol

Preparation

Patient is evaluated for contraindications, goals of treatment, and psychiatric or cosmetic indications.

Procedure

Skin cleansed and prepared
Botulinum toxin type A injected into corrugator and procerus muscles (typical total dose: 20–40 units)
Post-injection care includes avoiding rubbing the area for several hours

Frequency: Every 3–4 months as effects wear off

Duration: Each session lasts 10–20 minutes

Total Treatment Time: Ongoing, depending on indication

Equipment

Botulinum toxin type A preparation
Syringes with fine-gauge needles

Session Structure

Pre-Session

Informed consent, screening for contraindications, baseline symptom/cosmetic assessment.

Treatment Phase

Injection of botulinum toxin into targeted glabellar muscles.

Post-Session

Observation for immediate adverse effects; instructions to avoid massaging the area.

Expected Outcomes

Immediate

Mild injection site discomfort

Short Term

Reduction of frown lines within days
Possible mood improvement within weeks (psychiatric use)

Long Term

Maintenance of cosmetic or psychiatric benefit with repeat injections every 3–4 months

Side Effects

common

Injection site pain
Bruising
Headache

uncommon

Ptosis (drooping eyelid)
Asymmetrical facial expression

rare

Systemic botulinum toxin effects (very rare with cosmetic dosing)

Contraindications

absolute

Neuromuscular disorders
Known hypersensitivity
Active infection at site

relative

Pregnancy and breastfeeding (safety not established)

Patient Selection

ideal candidates

Adults with treatment-resistant depression seeking adjunctive therapy
Cosmetic patients seeking frown line reduction

screening required

Psychiatric history review
Neurological and medical history

Training Requirements

practitioner

Dermatologist
Plastic surgeon
Psychiatrist with procedural training

facility

Outpatient clinic or office setting

Research Evidence

Key Studies

Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2014;52:1–6.
Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH. Botulinum toxin for depression: a randomized controlled trial. J Psychiatr Res. 2015;70:63–67.

Limitations

Effect sizes modest; not yet standard of care for depression.

Cost Considerations

typical session cost: $300–$600 (cosmetic); psychiatric use not standardized

total treatment cost: Ongoing cost with repeat injections

insurance coverage: Cosmetic use usually not covered; psychiatric use experimental and not reimbursed

ux display: undefined

collapsible: undefined

heading: undefined

Integration Support

Concurrent Therapies

Psychotherapy
Antidepressant medication
Lifestyle interventions

Special Populations

Clinical Notes

Emerging evidence supports potential role in adjunctive treatment of depression.
Effects are temporary; repeat sessions required.
Minimal downtime; most patients resume activities immediately.

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists